E-GEOD-7377
Ontology highlight
ABSTRACT:
OTHER RELATED OMICS DATASETS IN: PRJNA100411
DISEASE(S): Normal Terminal Duct Lobular Unit,Benign Hyperplastic Enlarged Lobular Unit
PROVIDER: E-GEOD-7377 | ExpressionAtlas | 2015-07-27
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-GEOD-7377-analysis-methods.tsv | Tabular | |||
| E-GEOD-7377-atlasExperimentSummary.Rdata | Rdata | |||
| E-GEOD-7377-configuration.xml | Xml | |||
| E-GEOD-7377-percentile-ranks.tsv | Tabular | |||
| E-GEOD-7377.condensed-sdrf.tsv | Tabular |
Items per page: 5 1 - 5 of 50 |
Similar Datasets
Project description:Women with germline mtuation in BRCA1 have increased risk for developing hereditary breast cancer. The role of the epitheilum-assocaited niche during BRCA1-driven tumor intiation remains unclear. Here, we show that the pre-malignant stromal niche promotes epithelial prolifeation and BRCA1-driven cancer intiation in trans. Using single-cell RNA seq analysis of human pre-neoplastic BRCA1 and control breast tissue, we show that stromal cells provide numerous pro-proliferative paracrine signals inducing epithelial proliferation.
2021-11-17 | GSE174588 | GEO
Project description:Genome wide DNA methylation profiling of normal and breast cancer samples. The Illumina Infinium 450k Human DNA methylation Beadchip v1.1 was used to obtain DNA methylation profiles across approximately 485577 CpGs in breast cancer and normal samples. Samples included 40 normal, 80 breast cancer samples.
2015-03-11 | GSE66695 | GEO
Project description:SNP Expression profiling of human breast cancer: 29 tumor samples, 4 pure normal breat samples and 8 lymphocytes samples Keywords: Human Cancer
2007-02-20 | GSE5927 | GEO
Project description:Methylome-wide DNA methylation profiling of spatially separated breast tumor samples pre- and post-neoadjuvant chemotherapy (NAC) to characterize methylation heterogeneity alteration by NAC. The Illumina Infinium HumanMethylation450K Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 485,000 CpGs in the 47 samples derived from 8 breast cancer patients.
2019-01-31 | GSE106360 | GEO
Project description:<p>The identification of efficient and sensitive biomarkers for non-invasive tests is one of the major challenges in cancer diagnosis. To address this challenge, metabolomics is widely applied for identifying biomarkers that detects abnormal changes in cancer patients. Canine mammary tumors exhibit physiological characteristics identical to those in human breast cancer and serve as a useful animal model to conduct breast cancer research. Here, we aimed to provide a reliable large-scale metabolite dataset collected from dogs with mammary tumors, using proton nuclear magnetic resonance spectroscopy. We identified 55 metabolites in urine samples from 20 benign, 87 malignant, and 49 healthy control subjects. This dataset provides details of mammary tumor-specific metabolites in dogs and insights into cancer-specific metabolic alterations that share similar molecular characteristics.</p>
2022-02-24 | MTBLS2550 | MetaboLights
Project description:Epithelial ovarian cancer is morphologically and clinically heterogeneous. Transcriptional profiling has revealed molecular subtypes (referred to as M-bM-^@M-^\C-signaturesM-bM-^@M-^]) that correlate to biological as well as clinical features. We aimed to determine gene expression differences between malignant, benign and borderline serous ovarian tumors, and to investigate similarities to the intrinsic molecular subtypes of breast cancer. Global gene expression profiling was performed using Illumina's HT12 Bead Arrays and applied to 59 fresh-frozen ovarian tumors. SAM analysis revealed enrichment of cell cycel processes among the malignant tumors, in line with malignant tumors being highly proliferative. The borderline tumors were split between the malignant and benign tumor clusters, indicating that borderline tumors have both malignant and benign features. Furthermore, nearest centroid classification was performed applying previously published gene profiles for the ovarian cancer C-signatures and the intrinsic breast cancer subtypes, respectively, and showed significant correlations between the malignant serous tumors and the highly aggressive C1, C2 and C4 ovarian cancer signatures, and the basal-like breast cancer subtype. The benign and borderline serous tumors together were significantly correlated to the normal-like breast cancer subtype and the ovarian cancer C3 signature. The borderline tumors, on the other hand, correlated significantly to the Luminal A breast cancer subtype. These findings remained when analyzed in a large, independent dataset. The data in this study link the transcriptional profiles of serous ovarian cancer to the intrinsic molecular subtypes of breast cancer, in line with the shared clinical and molecular features between high-grade serous ovarian cancer and basal-like breast cancer, including an aggressive phenotype, frequent TP53 mutations and a high degree of genomic instability, and suggest that biomarkers and targeted therapies may overlap between these subsets of ovarian and breast cancers. Finally, the link between benign and borderline ovarian cancer and luminal breast cancer may indicate endocrine responsiveness in a subset of ovarian cancers. Total RNA obtained from serous ovarian adenocarcinomas, adenomas and borderline tumors. Gene expression profiling using Illumina's HT12 v4 bead arrays. Application of ovarian cancer molecular subtypes and intrinsic breast cancer subtypes using nearest centroid classification. KRAS and BRAF mutation analyses in the malignant and borderline tumors.
2014-08-15 | E-GEOD-57477 | biostudies-arrayexpress
Project description:Exosomes are a subset of extracellular vesicles shuttling proteins, RNA, DNA and lipids crucial for cell–to–cell communication. Recent findings highlighted that exosomes, by virtue of their cargo, may also contribute to breast tumor growth and dissemination of metastasis. Indeed, these vesicles are gaining great interest as non-invasive cancer biomarkers. However, little is known on exosome biological and physical properties from breast malignant lesions and even less by non–malignant lesions such as breast fibroadenoma. The latter, being a non-malignant lesion, is clinically managed by conservative approaches. However, the molecular features of fibroadenoma are still largely unknown. In this pilot study, we attempt to purify and explore the proteomic profiling of breast benign and tumor exosomes from breast fibroadenoma, HER2+ and triple negative patient tumors as well from continuous cell lines by combining experimental and semi-quantitative approaches (BT-549, MCF10-A and MDA-MB-231). Interestingly, proteome-wide analyses showed 49 common proteins across breast fibroadenoma, HER2+, triple-negative malignant lesions and model cell exosomes. This is the first feasibility study evaluating physicochemical composition and proteome of extracellular vesicles from breast benign, malignant primary cells and immortalized cells. Our preliminary results may hold promises for freshly isolated primary cells protein identification with possible implications in breast cancer precision medicine.
2022-05-31 | PXD027197 | Pride
Project description:Gene expression profiling of surgical biopsies from 74 breast cancer patients of different subtypes from Hamburg dataset. Fresh frozen pre-treatment surgical biopsy samples from breast cancer patients were analyzed on Affymetrix HGU133A.
2014-04-17 | E-GEOD-46184 | biostudies-arrayexpress
Project description:Epithelial ovarian cancer is morphologically and clinically heterogeneous. Transcriptional profiling has revealed molecular subtypes (referred to as “C-signatures”) that correlate to biological as well as clinical features. We aimed to determine gene expression differences between malignant, benign and borderline serous ovarian tumors, and to investigate similarities to the intrinsic molecular subtypes of breast cancer. Global gene expression profiling was performed using Illumina's HT12 Bead Arrays and applied to 59 fresh-frozen ovarian tumors. SAM analysis revealed enrichment of cell cycel processes among the malignant tumors, in line with malignant tumors being highly proliferative. The borderline tumors were split between the malignant and benign tumor clusters, indicating that borderline tumors have both malignant and benign features. Furthermore, nearest centroid classification was performed applying previously published gene profiles for the ovarian cancer C-signatures and the intrinsic breast cancer subtypes, respectively, and showed significant correlations between the malignant serous tumors and the highly aggressive C1, C2 and C4 ovarian cancer signatures, and the basal-like breast cancer subtype. The benign and borderline serous tumors together were significantly correlated to the normal-like breast cancer subtype and the ovarian cancer C3 signature. The borderline tumors, on the other hand, correlated significantly to the Luminal A breast cancer subtype. These findings remained when analyzed in a large, independent dataset. The data in this study link the transcriptional profiles of serous ovarian cancer to the intrinsic molecular subtypes of breast cancer, in line with the shared clinical and molecular features between high-grade serous ovarian cancer and basal-like breast cancer, including an aggressive phenotype, frequent TP53 mutations and a high degree of genomic instability, and suggest that biomarkers and targeted therapies may overlap between these subsets of ovarian and breast cancers. Finally, the link between benign and borderline ovarian cancer and luminal breast cancer may indicate endocrine responsiveness in a subset of ovarian cancers.
2014-08-15 | GSE57477 | GEO
Project description:Colorectal cancer (CRC) tumorigenesis proceedes through well defined clinical stages assoicated with charateristic mutations. To get a better understanding of CRC progression at the transcriptional level, we performed transcriptome profiling on samples from normal colonic tissues, pre-malignant adenomas, carcinomas and metatases. We used Affymatrix microarry to get a broad view of gene expression during colorectal cancer progression and identified significantly differentially expressed genes between different stages
2016-05-13 | GSE77953 | GEO